Nasdaq News

Investors in Yum! Brands Inc (Symbol: YUM) saw new options begin trading today, for the August 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the YUM options chain for the new August 21st contracts and identified one put and one call

Investors in Orange (Symbol: ORAN) saw new options become available today, for the February 2021 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 246 days until expiration the newly available contracts re

Investors in Enterprise Products Partners L.P. (Symbol: EPD) saw new options begin trading today, for the August 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EPD options chain for the new August 21st contracts and identified on

Investors in ArcelorMittal SA (Symbol: MT) saw new options become available today, for the August 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MT options chain for the new August 21st contracts and identified one put and one ca

Investors in SL Green Realty Corp (Symbol: SLG) saw new options begin trading today, for the February 2021 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 246 days until expiration the newly trading cont

The following are today's upgrades for Validea's Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that have low P/B and P/E ratios, along with low debt and solid long-term earnings growth.

The following are today's upgrades for Validea's Growth/Value Investor model based on the published strategy of James P. O'Shaughnessy. This two strategy approach offers a large-cap value model and a growth approach that looks for persistent earnings growth and strong relative

The following are today's upgrades for Validea's Earnings Yield Investor model based on the published strategy of Joel Greenblatt. This value model looks for companies with high return on capital and earnings yields.

The following are today's upgrades for Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.

The following are today's upgrades for Validea's Book/Market Investor model based on the published strategy of Joseph Piotroski. This value-quant strategy screens for high book-to-market stocks, and then separates out financially sound firms by looking at a host of improving f

The following are today's upgrades for Validea's Price/Sales Investor model based on the published strategy of Kenneth Fisher. This value strategy rewards stocks with low P/S ratios, long-term profit growth, strong free cash flow and consistent profit margins.

The following are today's upgrades for Validea's Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance.

The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.

Stocks just couldn’t get anything going on Wednesday after all the good news that recently dropped, leading to a volatile session for the market that ultimately ended the three-day winning streaks for two of the major indices. The Dow slipped 0.65% (or about 170 points) to

While there was an expectation that we would see some resurgence in COVID-19 cases as economies re-opened, the rash of new or rising outbreaks are weighing on markets.

It's easy to find $20 tech stocks right now. The COVID-19 crisis took the wind out of Wall Street's sails in 2020, and bargain stocks are plentiful even after a dramatic recovery in May and June.

Aimmune Therapeutics (NASDAQ: AIMT) has performed significantly worse than the broader market of late. The company's stock fell by more than 50% during the first quarter of the year, and even though it has rebounded somewhat, Aimmune's shares are still down by 43% year to date.

Intercept Pharmaceuticals (NASDAQ: ICPT) and Madrigal Pharmaceuticals (NASDAQ: MDGL) are two stocks that have moved in opposite directions of late. Intercept's stock has slid by 36% since the year started, while Madrigal's stock is up by 22% over the same period. However, histor

Pfizer (NYSE: PFE) and Merck (NYSE: MRK) are both multinational pharmaceutical heavyweights, complete with massive development pipelines, numerous subsidiaries, and consistently profitable operations. With nearly identical market caps in the $200 billion range, Merck and Pfizer

Shares of Apple (NASDAQ: AAPL) rose to record highs on Wednesday, a few days after the company revealed that over a half-trillion dollars transacted over its App Store ecosystem in 2019. The staggering figure demonstrated how powerful the company's platform has become and it hig